Group 1 - The core viewpoint of the article highlights that Valiant Bio-B (09887) has seen a significant stock increase of over 8%, currently trading at 64.75 HKD with a transaction volume of 44.92 million HKD [1] - Valiant Bio announced that its dual-specific antibody LBL-034, developed on the TCE technology platform LeadsBody, has received Fast Track designation from the FDA for the treatment of relapsed/refractory multiple myeloma [1] - Huafu Securities released a report stating that Valiant Bio is comprehensively laying out next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC, with a focus on "technology platform + innovative targets" [1] Group 2 - The company has consistently developed its technology platforms since 2015 with the X-body platform, followed by the LeadsBody platform in 2016, and has accumulated expertise in dual and tri-antibody technologies [1] - Valiant Bio's pipeline covers cutting-edge areas such as immune checkpoints and multi-specific antibodies, aiming to create a differentiated product line [1]

Core Viewpoint - Huafu Securities initiates coverage on Weili Zhibo (09887) with a "Buy" rating, projecting revenue for 2025-2027 to be 1.80, 0.94, and 0.10 million yuan, with growth rates of 833%, -48%, and -90% respectively [1] Group 1: Company Overview - The company is focused on next-generation tumor immunotherapy through its agonist platform, TCE platform, and ADC, establishing a comprehensive layout [1] - The company has consistently emphasized "technology platform + innovative targets" since 2015, covering cutting-edge fields such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline [1] Group 2: Clinical Developments - LBL-024 (PDL1/4-1BB bispecific antibody) shows historical best data in lung neuroendocrine carcinoma, with excellent efficacy in first-line SCLC and promising preliminary efficacy in NSCLC [1] - LBL-024 enhances the efficacy of second-generation CAR-T therapy, demonstrating low liver toxicity with ≥3 grade liver enzyme elevation at only 1.3%, comparable to PD-1 monoclonal antibodies, indicating superior safety and a broad therapeutic window [1] - LBL-024 is the first 4-1BB targeted molecule to reach critical clinical stages globally, with ongoing clinical research approved in multiple cancer types including SCLC, BTC, OC, and NSCLC, showing encouraging clinical results [1] Group 3: Additional Pipeline Insights - LBL-034 (GPRC5D/CD3 bispecific antibody) demonstrates improved safety and dosage intensity, with a 2:1 structure enhancing TAA binding while balancing efficacy and safety [2] - In I/II clinical studies, LBL-034 achieved an ORR of 77.8% at a dosage of 400μg/kg and 90.9% at 800μg/kg, comparable to CAR-T efficacy [2] - Other pipeline developments include BDCA2×TACI with IND expected in the second half of 2025, and CD19/BCMA/CD3 trispecific antibody IND anticipated in Q1 2026 [2]

Group 1 - The core viewpoint of Huafu Securities is that it initiates coverage of Weilizhibo (09887) with a "Buy" rating, projecting revenues of 180 million, 94 million, and 10 million yuan for 2025-2027, with growth rates of 833%, -48%, and -90% respectively [1] - The company is strategically positioned in next-generation tumor immunotherapy through its agonist platform, TCE platform, and ADC, focusing on "technology platform + innovative targets" to cover cutting-edge fields such as immune checkpoints and multi-specific antibodies [1] Group 2 - LBL-024 (PDL1/4-1BB bispecific antibody) shows historical best data in lung neuroendocrine carcinoma, with excellent efficacy in first-line SCLC and promising preliminary efficacy in NSCLC; it demonstrates low liver toxicity with ≥3 grade liver enzyme elevation at only 1.3%, comparable to PD-1 monoclonal antibodies [2] - LBL-024 is the first 4-1BB targeted molecule to reach critical clinical stages globally, with ongoing clinical research approved in multiple cancer types including SCLC, BTC, OC, and others, indicating its potential as an effective anti-tumor drug with broad indications [2] Group 3 - LBL-034 (GPRC5D/CD3 bispecific antibody) exhibits superior safety and dosage intensity, achieving an overall response rate (ORR) of 77.8% at 400 μg/kg and 90.9% at 800 μg/kg, comparable to CAR-T efficacy, with no dose-limiting toxicity or ≥3 grade CRS observed [3] - Other pipelines include BDCA2×TACI expected to file IND in the second half of 2025, and a CD19/BCMA/CD3 trispecific antibody IND anticipated in Q1 2026, along with DLL3 TCEADC expected to file IND in the first half of 2027 [3]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Takeda Pharmaceutical has officially commenced, marking a significant milestone in China's innovative drug industry with a potential deal value of up to $11.4 billion, setting a record for Chinese innovative drugs going global [1][3]. Group 1: Collaboration Details - Innovent Biologics will receive an upfront payment of $1.2 billion, which includes a $100 million strategic equity investment and up to $10.2 billion in milestone payments [1]. - The collaboration focuses on the global development and commercialization of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, specifically IBI363 and IBI343, along with early-stage project IBI3001 [1][7]. - IBI363 is recognized as one of the fastest-developing PD-1/IL-2 products globally, with ongoing clinical trials, including a pivotal Phase III study for squamous non-small cell lung cancer [6][10]. Group 2: Market Position and Financial Performance - Innovent Biologics has become one of the largest biopharmaceutical companies in China since its establishment in 2011, with a diverse product portfolio covering oncology, autoimmune diseases, metabolism, and ophthalmology [10]. - The company reported a revenue of 5.953 billion yuan in the first half of the year, a 50.6% year-on-year increase, and achieved profitability with a profit of 834 million yuan [11]. - As of the end of July, Innovent had over 14 billion yuan in cash reserves, positioning itself well for future growth and development [10].

Core Insights - The company is positioned as a leader in next-generation tumor immunotherapy, focusing on addressing diseases that current therapies, such as PD-1/PD-L1 antibodies, cannot treat [1] - The company has established a robust R&D pipeline with 14 new drugs, including 6 in clinical stages and 4 with leading global clinical progress [1] - The 4-1BB co-stimulation signal market has significant potential, with the drug LBL-024 showing promising clinical data and competitive advantages over existing treatments [1][2] Group 1 - The company utilizes three major technology platforms to develop a comprehensive pipeline of tumor drugs, including ADC, IO2.0, and TCE [1] - LBL-024, a 4-1BB targeting drug, has demonstrated a doubling of median overall survival (mOS) in later-line ep-NEC compared to existing therapies and shows superior clinical data in 1L SCLC [1] - The company is expanding LBL-024's indications to include 8 additional cancers, indicating a broad potential market space [1] Group 2 - The TCE technology platform has been validated through clinical data, with LBL-034 showing potential efficacy and safety advantages over competitors [2] - The CD3/GPRC5D TCE drug LBL-034 activates T cells conditionally in tumor microenvironments, with upcoming ASH2025 data expected to further confirm its advantages [2] - The company has plans for new generation TCE and TCE ADC platforms targeting solid tumors, with the CD3/MUC16 TCE positioned as a top contender globally [2] Group 3 - The company is currently in a new drug development investment phase, with projected revenues of 175 million, 314 million, and 187 million yuan for 2025, 2026, and 2027 respectively [2] - The net profit forecast indicates losses of 200 million, 99 million, and 262 million yuan for the same years, reflecting the ongoing investment in R&D [2] - The company is recognized as a leader in 4-1BB co-stimulation and has a rich reserve of TCE platform projects, receiving an "Accumulate" rating for its first coverage [2]